More recently, a number of biological mechanisms have been elucidated by which these drugs might improve peripheral skeletal muscle function.
9 Angiotensin II has direct deleterious effects on
skeletal muscle structure and function in experimental conditions
10,
11 and may impair both macrovascular and microvascular
endothelial function, and hence, blood flow in peripheral vascular beds.
12 Angiotensin II also promotes
chronic inflammation,
13 which is in turn thought to be an important driver of sarcopenia—the age-related loss of muscle mass and strength that underpins impaired physical performance in many older people. Conversely use of ACEi and ARBs can ameliorate these deleterious effects in experimental conditions;